Boston, Massachusetts-based Vertex Pharmaceuticals Incorporated (VRTX ... and do not necessarily reflect those of Nasdaq, Inc. With headquarters in the heart of Chicago's financial district ...

MaxCyte, Inc., a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell therapeutics, ...

Vertex was founded in 1989 and has its global headquarters in Boston ... and reference the “Vertex Pharmaceuticals Third Quarter 2024 Earnings Call.” The conference call will be webcast ...

Vertex Pharmaceuticals Inc. ( (VRTX) ) has released its Q3 earnings. Here is a breakdown of the information Vertex Pharmaceuticals Inc.

Vertex Pharmaceuticals Option Volume And Open Interest Over Last 30 Days Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment ...

Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko ...

Nov 4 (Reuters) - Vertex Pharmaceuticals (VRTX.O), opens new tab raised its annual revenue forecast on Monday after it beat third-quarter estimates on demand for its cystic fibrosis (CF ...

Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko ...

Reshma Kewalramani; President, Chief Executive Officer, Director; Vertex Pharmaceuticals Inc Stuart ... I'm very pleased to share that we began the global Phase 2 RAINIER study of pove in patients ...

Vertex Pharmaceuticals (VRTX) came out with quarterly earnings of $4.38 per share, beating the Zacks Consensus Estimate of $4.13 per share. This compares to earnings of $4.08 per share a year ago.